Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities
Net Loss	$ (22,491)	$ (46,126)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation	4,134	14,986
Depreciation and amortization	18	162
Impairment loss on operating lease	66	136
Loss on disposal of fixed assets	71	77
Equity investment in Lighthouse Pharmaceuticals, Inc.	(78)	0
Non-cash goodwill impairment charge	0	825
Non-cash intangible impairment charge	5,900	0
Amortization of (discount) premium on available for sale investments	(1,313)	83
Change in deferred tax liabilities due to acquisition of Novosteo, Inc.	(248)	(284)
Changes in operating assets and liabilities, net of acquisitions:
Prepaid expenses and other current assets	2,272	2,396
Right of use assets and lease liabilities	192	0
Other assets	0	175
Accounts payable	(161)	(5,329)
Accrued expenses and other current liabilities	(576)	(5,304)
Net cash used in operating activities	(12,214)	(38,203)
Cash flow from investing activities:
Purchase of investments	(95,116)	(66,767)
Proceeds from maturities of investments	84,514	55,495
Cash acquired from Novosteo, Inc.	0	10,593
Note receivable	(500)	0
Proceeds from disposal of fixed assets	90	70
Purchase of property and equipment	(136)	(55)
Net cash used in investing activities	(11,148)	(664)
Cash flows from financing activities:
Payments of finance leases	(6)	(31)
Proceeds from issuance of common stock upon exercise of stock options	92	148
Proceeds from issuance of common stock in connection with open market sales agreement, net of issuance costs	0	608
Net cash provided by financing activities	86	725
Effect of exchange rate changes on cash	329	227
Net decrease in cash and cash equivalents	(22,947)	(37,915)
Cash and cash equivalents at beginning of period	44,579	69,724
Cash and cash equivalents at end of period	21,632	31,809
Supplemental disclosures of non-cash information:
Net assets acquired of Novosteo, Inc. in exchange for common stock	0	16,503
Right-of-use assets obtained in exchange for new operating lease liabilities	0	256
Right-of-use asset and financing lease liability reduction as a result of lease modification	(70)	0
Right-of-use asset and operating lease liability reduction as a result of lease modification	$ 0	$ (640)